Etaracizumab

Etaracizumab, also known as MEDI-522, trade name Abegrin, is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer,^[1] ovarian cancer^[2] and various other types of cancer.^[3] It is manufactured by MedImmune.^[1]

Etaracizumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	alpha-v beta-3 integrin
Clinical data
Trade names	Abegrin
ATC code	none
Identifiers
CAS Number	892553-42-3 N
ChemSpider	none
UNII	41W9MFI160
KEGG	D09342 Y
Chemical and physical data
Formula	C6392H9908N1732O1996S42
Molar mass	144302.22 g·mol−1
NY (what is this?)  (verify)

It is an enhanced iteration of Vitaxin, also known as MEDI-523. Both are derived from the mouse antibody LM609.^[4]